This is what inspires us. For a child suffering from a painful laceration or a person who can't see because of a cataract, they need their lives to get better, to feel normal again. We spend an inordinate amount of time developing a few drugs. We seek to enhance the lives of everyone we interact with. Follow us...

MSK-3001

MSK-3001 is an investigational ophthalmic drug used during cataract surgery to dilate the pupil and prevent intraoperative floppy iris syndrome. It is a proprietary, sterile, stable, and sulfite free formulation of lidocaine and epinephrine intended to replace pharmacy-compounded versions of epi-Shugarcaine. There has been drug shortages of preservative free, sulfite free epinephrine used for pharmacy compounding of epi-Shugarcaine. This drug shortage is due to interrupted production and discoloration and particulates formation in certain lots from the sole United States manufacturer.

MSK-3001 is intended for intracameral administration (injection into the anterior chamber of the eye) during cataract surgery. Cataract removal is one of the five most common outpatient procedures according to the Centers for Disease Control and Prevention. About three million cataract removals are performed every year in the United States. The procedure costs about $3,000 and is more common in the elderly. We plan to develop the first FDA-approved epi-Shugarcaine product that is single-dosed and consistently manufactured to high standards.